Description

Haemonetics Corporation: Accelerating International Expansion Strategy To Change The Game! 

Haemonetics Corporation reported solid financial results for the second quarter of fiscal year 2025, reflecting both positive growth trajectories and some ongoing challenges. The company achieved a total revenue of $346 million, marking a 9% increase on a reported basis and 4% growth organically, primarily driven by its Hospital business. The adjusted earnings per share for the quarter were $1.12, a 13% increase compared to the previous year, underlining improved financial performance.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!